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Abstract
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. Their
incidence in the esophagus is 1%–3%. Never has a GIST been documented to directly invade the
lung. We report a primary esophageal GIST with direct invasion into the lung parenchyma,
presenting predominantly with respiratory symptoms. We include a retrospective literature
review. Although the principle 'common things are common' usually guides our everyday clinical
practice, this case emphasizes that rare entities can mimic common pathologies and underlines the
importance of having a clearly defined differential diagnostic list which should be meticulously
scrutinized.
Introduction
Gastro-Intestinal Stromal Tumors (GISTs) belong to the
group of gastrointestinal mesenchymal tumors (GIMTs).
These include myogenic tumors (leiomyomas or leiomy-
osarcomas), neurogenic tumors (schwannomas) and
GISTs. They arise from the gastrointestinal (GI) wall, and
they are distributed from the esophagus to the rectum. [1-
4]
These are now defined as spindle cell, epithelioid or occa-
sionally pleiomorphic mesenchymal tumors that express
c-kit protein immunopositivity (CD117), which is their
major diagnostic criterion. [2,3,5]
Although generally rare, they are the most common mes-
enchymal neoplasms of the GI tract, and encompass most
tumors previously classified as gastric and intestinal
smooth muscle or neural cell tumors [1,2].
Case report
A 58 year old lady was referred by her General Practitioner
(GP) after presenting with a 3 day history of moderate left
sided pleuritic chest pain radiating to the left shoulder,
low grade pyrexia and frontal headaches. She experienced
no cough, hemoptysis, or shortness of breath but had
recurrent episodes of upper respiratory tract infections in
the past five months. There was no significant past medi-
cal history and she was a lifetime non smoker.
Clinical examination revealed left lower lobe crackles.
Routine blood tests revealed a White Cell Count of 11.82
109/lt and a C-Reactive protein (CRP) of 164 mg/lt. The
chest radiograph (CxR) demonstrated a raised left hemi
diaphragm with volume loss in the left lower lobe (Fig 1).
Due to the equivocal findings on the CxR, she underwent
a Computerized Tomography (CT) (Fig 2,) of her thorax
which revealed a large necrotic mass within the left lower
lobe extending into the posterior mediastinum, surround-
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ing the aorta and in close contact with the distal esopha-
gus. It extended to the gastric fundus through extensive
invasion of the left hemi-diaphragm. No mediastinal lym-
phadenopathy was reported.
A CT guided biopsy was performed and the histology
showed a spindle cell tumor. Immunohistochemistry
revealed the tumor cells to be positive for CD 34, h-cald-
esmon (muscle marker) and focally positive for epithelial
membrane antigen. The possibility of a 'solitary fibrous
tumor' was raised as the clinical history indicated that this
was primarily a chest tumor. She was subsequently
referred to our team.
At thoracotomy the tumor was invading the left lower
lobe but large part of it was descending in the posterior
mediastinum and through the hiatus. The initial incision
was extended to a left thoracolaparotomy and the mass
was resected en block performing a left lower lobe lobec-
tomy, a distal esophagectomy, partial gastrectomy and
diaphragmatic resection with primary esophagogastric
anastomosis and diaphragmatic reconstruction.
On histopathological examination the tumor was pre-
dominantly composed of spindle shaped cells, with oval
nuclei and eosiniphilic cytoplasm. Focal myxoid change
was present. There was some nuclear pleomorphism and
in areas the mitotic count was more than 5/50 high power
field (HPF). Although the tumor was predominantly
within the lung parenchyma, it was seen to be arising
from the esophageal wall, where it extended into the lam-
ina propria and attenuated the overlying esophageal squa-
mous epithelium (figure 3).
Slide depicting H & E stain of the GIST within the esophageal  wall (Magnification power 5×) Figure 3
Slide depicting H & E stain of the GIST within the esophageal 
wall (Magnification power 5×).
CT scan depicting a well circumscribed tumor measuring 10  cm antero-posteriorly, 14 cm transversely and 9 cm cranio- caudally enveloping the descending aorta and extending into  the posterior mediastinum Figure 2
CT scan depicting a well circumscribed tumor measuring 10 
cm antero-posteriorly, 14 cm transversely and 9 cm cranio-
caudally enveloping the descending aorta and extending into 
the posterior mediastinum.
Chest radiograph showing a raised left hemi-diaphragm and  volume loss in the left lower lobe Figure 1
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On immunohistochemistry, the tumor cells revealed
strong diffuse positivity for CD 34 and CD 117 (c-kit) (fig-
ure 4). The cells were focally positive for the muscle mark-
ers including h-caldesmon, desmin, actin and myoglobin.
Focal positivity was also seen with epithelial membrane
antigen and cytokeratin (MNF 116). The tumor was nega-
tive for S 100 protein CD 99, Thyroid transcription factor
(TTF 2) and calretinin.
On the basis of the above findings, the tumor was classi-
fied as a gastrointestinal stromal tumor arising from the
esophageal wall and extending into the lung parenchyma.
As the tumor measured more than 10 cm in size, with a
mitotic count over 5/50 HPF extending into the lung
parenchyma, it was categorized as a high risk GIST.
Following post-operative recovery, the patient was
referred to the oncology team for assessment regarding
adjuvant therapy.
Discussion
Incidence
According to the largest epidemiologic analysis done so
far, which included 1458 recorded cases [6], as well as
studies by Miettinen et al [2], GISTs typically present in
adults over 40–50 years and only exceptionally in chil-
dren [2,7]. Their incidence according to anatomic location
varies among different studies and ranges between 51%–
70% in the stomach, 25%–36% in the small intestine,
5%–7% in the colon, rectum and appendix, and 1%–3%
in the esophagus. Primary GISTs can be found in the
omentum, mesentery or retroperitoneum, unrelated to
the tubular GI tract, but most in these sites are metastatic
from gastric or intestinal primaries [2,4,6,8-10].
Histologic features
GISTs can exhibit either a spindle, epithelioid or mixed
cytomorphology. Spindle cell GISTs are usually arranged
in fascicles, while epithelioid GISTs are arranged in sheets
or nests. Mitotic activity is variable. Necrosis can be
present. Nuclear pleomorphism is rare, usually focal.
Immunohistochemical features and histogenesis
According to a concensus approach on the diagnosis of
GISTs [5] the term "GIST" should only apply to neo-
plasms displaying KIT (CD117) immunopositivity with
very rare exceptions. Recently, some GISTS without the
KIT mutation have been found to express a mutation in
another tyrosine kinase receptor gene, the PDGFRa gene.
It is important to mention that normal Kit-positive cells in
abdominal soft tissues include mast cells present in the
wall of the GI tract and the interstitial cells of Cajal (intes-
tinal pacemakers) present around the myenteric plexus
[3]. Although the origin of GISTs is not fully understood,
their association with the Cajal cells suggests that these
cell subsets could represent a multipotential stem-cell like
population, which is the logical candidate for GIST his-
togenesis [1]. Positivity for nestin (90%–100%) and
CD34 (70%) are also characteristic but not specific [2].
Prognostic factors
Amongst histologic criteria the most important prognos-
tic factor is mitotic index [1,2,11]. Other less important
criteria are high cellularity, marked pleiomorphism and
presence of histological necrosis [1]. Among clinical crite-
ria the size of the tumor is the most important prognostic
factor [2,8]. Other less important clinical criteria are mac-
roscopic invasion into surrounding structures, metastasis
at diagnosis, peritoneal dissemination, tumor rupture at
surgery and incomplete resection [1,5,8]. However, low
mitotic index and small size do not absolutely guarantee
a benign clinical course. Therefore, instead of classifying
lesions as either benign or malignant, current guidelines
categorise GISTs as low, intermediate and high risk based
on size and mitotic index[12]. High risk GISTs have an
increased potential for diffuse intra-abdominal spread
and liver metastasis, which are the two most common
modes of dissemination [3,8]. Distant metastasis to other
sites, especially bone and lung, are relatively rare [3,8].
Clinical presentation of GISTs
The most frequent clinical manifestations are occult gas-
trointestinal bleeding, pain, dyspepsia, fatigue associated
with anemia, palpable mass, perforation or rarely obstruc-
tion [13]. In a study of 17 esophageal GISTs [4], seven pre-
sented with dysphagia, two had cough, one had
gastrointestinaI bleeding, and two had weight loss. There
has been no report of a direct local invasion of a GIST
tumor to the lung and only in one study is the lung men-
Slide depicting c-KIT (CD 117) stain of the GIST with diffuse  positivity (Magnification power 20×) Figure 4
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tioned in association with a GIST tumor and only as met-
astatic site from an intestinal primary [8].
Management-Survival
Complete surgical resection remains the standard treat-
ment for primary, non metastatic GISTs. The tumor is
often fragile, with haemorrhage or necrosis, and it may
have a pseudocapsule. Meticulous surgical technique is
necessary to remove the tumor en-bloc and avoid intraop-
erative rupture which is associated with poor prognosis
[11,13]. A wide resection margin is not needed, however
local peritoneal seeding is common and a local peritonec-
tomy should be performed when feasible [13]. Lymph
node metastases are rare hence routine regional lym-
phadenectomy is not recommended [13,14]. Given the
potential malignant behavior of benign appearing GISTs,
at least one group of investigators believes that all should
be classified as malignant tumors on a low-to-high grad-
ing scale rather than on a benign-versus-malignant basis
[15]. Malignant GISTs are highly refractory to conven-
tional chemotherapy and radiotherapy [6,8]. Five year
survival following complete surgical resection varies rang-
ing between 35%–60% [13].
Since 1988 the treatment of GISTs has changed dramati-
cally after discovering that the majority of these tumors
have oncogenic mutations of the KIT receptor tyrosine
kinase [16]. As well as being a useful diagnostic marker,
KIT became an excellent therapeutic target [17]. Imatinib
mesylate, is a molecule that selectively inhibits the enzy-
matic activity of the ABL and BCR-ABL fusion protein,
PDGF-receptor and KIT tyrosine kinases. Imatinib
mesylate inhibits the mutated KIT receptor leading to
apoptosis and decrease in proliferation of tumor cells
[17,18]. Several trials are still ongoing but preliminary
results support the effectiveness and safety of its use in
unresectable, recurrent and metastatic tumors and has
been reviewed systematically [14].
Comments
Gastrointestinal stromal tumors are rare in the esophagus
and have never been documented before this case report
to directly invade the lung. Despite the limited experience,
complete surgical resection is indispensable and adjuvant
imatinib mesylate therapy is recommended in cases of
high risk. Therefore surgeons, physicians and especially
pathologists should keep in mind the possibility of GISTs
when a lesion mainly occupying the lung is shown radio-
logically to involve the esophagus or stomach. In such
cases immunohistochemical investigations should
include CD117, CD34 and muscle markers so that an
accurate diagnosis is reached, and the appropriate treat-
ment instituted.
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